ContractDevelopment and Supply Agreement • February 21st, 2017 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances)
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
ContractSeattle Genetics Inc /Wa • February 21st, 2017 • Biological products, (no disgnostic substances)
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
ContractLetter Agreement • February 21st, 2017 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances)
This letter agreement (the “Second Amendment”) confirms the Parties’ agreement to amend the Supply Agreement to change the price per gram/per Batch (the “Price”) for SGD 1006 set forth in Appendix C to the Supply Agreement. The purpose of the pricing revision is to a) capture the cost of the [*] used in the manufacture of SGD-1006, b) capture the operational efficiencies gained during the manufacturing of the [*] c) capture the increased labor and overhead costs in the [*], and d) capture the [*] inventory remaining from production [*]. Beginning as of January 1, 2017, certain [*], as listed in the second table below, that were previously provided [*] in accordance with cGMP, Applicable Laws and the Quality Agreement, and the [*]. Through 2016, these [*] had been provided by or purchased separately by [*]. In addition, effective as of January 1, 2017, any [*] from each batch production will now be owned by [*].
